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journal homepage: www.urol-sci .comEditorial commentKetamine cystitisdA long-lasting burning issue in TaiwanOn June 27, 2015, the “Color Play Asia” party was held at the For-
mosa Fun Coast water park in Bali District, New Taipei, Taiwan. At
approximately 8:30 PM, a large explosion occurred after a cloud of
ﬂammable color powder caught ﬁre and caused various degrees
of burn injury in 495 people; 199 people were in critical condition.
Most of the injured were students in their twenties and late teens
who had just started their summer vacation. Many injured remain
in the acute stage; however, society and the government are
expecting they will have an undeniably difﬁcult and time-
consuming burn rehabilitation. This event has attracted great
attention and concern of the public and the authorities. However,
another long-lasting burning issue that young people should be
aware of in Taiwan is ketamine cystitis (KC).
Since 2003, ketamine has been classiﬁed as a Schedule III
controlled drug in Taiwan and has been used by young people
and teenagers as a recreational drug in night clubs and parties for
approximately a decade. According to the Anti-Drug Report 2014
by the government of Taiwan, ketamine is the most common
drug of abuse and >28,000 individuals tested positive for ketamine
in 2013.1 An increasing number of ketamine abusers have severe
lower urinary tract symptoms (LUTS) and bladder pain because of
acute and chronic ulcerative cystitis. Typical clinical features of
KC such as denudation of the mucosa and severe inﬂammation in
the bladder are similar to a burn injury. Long-term bladder inﬂam-
mation may cause ﬁbrosis of the bladder wall and eventually a con-
tracted bladder. As in the treatment strategy of a burn injury,
patients with KC require appropriate management of their severe
LUTS and bladder pain in the acute stage, and the prevention of
bladder contracture and upper urinary tract dysfunction in the
chronic stage.
Understanding the pathophysiology is the basis of good treat-
ment; however, the pathogenesis of bladder dysfunction under
this condition remains unclear. Ketamine and its active metabolites
can be measured in high quantities in the urine of patients using
ketamine.2 Chu et al3 proposed that KC may result from the two
active metabolites of ketamine: norketamine and hydroxynorket-
amine. It is conceivable that ketamine and its active metabolites
may accumulate in the urine and induce signiﬁcant bladder
irritation.
Recent pathological research on the urinary bladder in ketamine
addiction that employed mice reveals mononuclear inﬁltration,
which is very similar to that of the clinical situation of interstitial
cystitis/painful bladder syndrome. By using a long-term keta-
mine-treated rat model, Gu et al4 demonstrated that ketamine
and its urinary metabolites, disrupted the proliferation of bladder
epithelial cells, and resulted in a defect in the bladder epithelialhttp://dx.doi.org/10.1016/j.urols.2015.08.004
1879-5226/Copyright © 2015, Taiwan Urological Association. Published by Elsevier Ta
creativecommons.org/licenses/by-nc-nd/4.0/).barrier. Subsequent leakage of urinary potassium causes a stress
response in the bladder and provokes cystitis.4 There may be a
decrease in the cholinergic neurons of the urinary bladder in
ketamine-treated animals.5 It has also been reported that the char-
acteristics of mouse bladder contractility may change after chronic
ketamine treatment.6 Using a rat model of KC, Chuang et al7 state
that ketamine initiated the upregulation of the expression of
cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS),
and endothelial nitric oxide synthase (eNOS), which may have an
important role in contributing to ketamine-induced alterations in
micturition patterns and ulcerative cystitis. Tissue samples from
23 patients with KC have demonstrated immunopositivity for
many inﬂammation markers, based on staining of the urothelium,
vessel walls, and smooth muscle. COX-2 staining differed signiﬁ-
cantly between inﬂammatory levels in the urothelium and smooth
muscle, and iNOS staining differed signiﬁcantly between inﬂamma-
tory levels in smooth muscle. A positive correlation between the
percentage of phos-S6epositive cells and inﬂammation levels in
the urotheliumwas also evident. These enzymesmay be reliable in-
ﬂammatory markers for KC.8 In an in vitro urothelial cell line study,
Shen et al9 found that ketamine arrested cells in the G1 phase and
increased the sub-G1 population, and increased the barrier perme-
ability of these cell lines. By analyzing global gene expression in the
ketamine-treated mouse bladders, Shen et al9 stated that cytotox-
icity and keratin gene downregulation may have a critical role in
ketamine-induced cystitis.
Ketamine is the “pathogen” of KC; therefore, the cessation of ke-
tamine use is a key step in treatment. Many KC patients experi-
encing bladder pain tend to continue using ketamine for pain
relief and thus decrease the success rate of drug withdrawal. There-
fore, a short period of intensive analgesia may be necessary to over-
come KC-related pain and to increase the chance of total abstinence
from ketamine. Nonsteroidal anti-inﬂammatory drugs are
commonly used in the treatment of these patients. Clinicians
should closely monitor the renal function of patients because the
kidneysmay be damaged by analgesics. Many intravesical therapies
such as chondroitin sulfate, pentosan polysulfate, and hyaluronic
acid [e.g., Cystistat (sodium hyaluronate) (Bioniche Life Sciences
Inc., Belleville, Ont., Canada)], have been used to repair the injured
urothelium and relieve the symptoms caused by KC.10,11 However,
long-term and placebo-controlled studiesdalthough difﬁcult to
execute in KC patientsdare required to establish a standard treat-
ment strategy. For patients with a contracted bladder because of
irreversible ﬁbrotic changes of the bladder secondary to prolonged
inﬂammation, augmentation enterocystoplasty is a treatment that
may improve symptoms and the quality of life. However, theiwan LLC. This is an open access article under the CC BY-NC-ND license (http://
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from drug use should be emphasized because recirculation of keta-
mine metabolites by the intestine used in augmentation enterocys-
toplasty may result in a very high concentration of circulating
ketamine and cause serious complications (e.g., renal failure,
convulsion).12
Upper urinary tract injury is another important issue in keta-
mine abusers. Hydronephrosis with obstructive uropathy is a com-
mon clinical presentation of ketamine abusers. This may result
from ureteral wall thickening, stricture, vesicoureteral reﬂux, or
ureteropelvic junction stenosis.13,14 Ketamine abuse may also cause
acute renal infarction, which subsequently impairs renal function.15
Therefore, urologists should always be aware of the upper urinary
tract function in patients with KC.
As with burn rehabilitation, patients with KC should be treated
on a case-by-case basis with the involvement of a multidisciplinary
team (e.g., urologists, psychiatrists, social workers, dedicated
nurses, and family members). A long-term drug rehabilitation pro-
gram may help reduce the complications of KC. More attention
from the authorities and medical system will support ketamine
abusers returning to a normal social life.
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